Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)
NCT03945292
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
40
Enrollment
INDUSTRY
Sponsor class
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
DRUG:
Fazisiran Injection
OTHER:
Placebo
Sponsor
Arrowhead Pharmaceuticals